Evidence map›Paper›PMID 25733777›Full record

Trial reportMediators of inflammation2015

Effects on serum fractalkine by diet and omega-3 fatty acid intervention: relation to clinical outcome.

Kristian Laake, Ingebjørg Seljeflot, Morten Wang Fagerland, Ida Unhammer Njerve, Harald Arnesen, Svein Solheim

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Mediators of inflammation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Kristian LaakeCenter for Clinical Heart Research, Department of Cardiology, Oslo University Hospital, Ullevål, Postboks 4956 Nydalen, 0424 Oslo, Norway ; Faculty of Medicine, University of Oslo, Postboks 1078 Blindern, 0316 Oslo, Norway ; Center for Heart Failure Research, Institute for Experimental Medical Research, Oslo University Hospital, Ullevål, Kirkeveien 166, 0407 Oslo, Norway.ORCID 0000-0003-2925-0823
Ingebjørg SeljeflotCenter for Clinical Heart Research, Department of Cardiology, Oslo University Hospital, Ullevål, Postboks 4956 Nydalen, 0424 Oslo, Norway ; Faculty of Medicine, University of Oslo, Postboks 1078 Blindern, 0316 Oslo, Norway ; Center for Heart Failure Research, Institute for Experimental Medical Research, Oslo University Hospital, Ullevål, Kirkeveien 166, 0407 Oslo, Norway.
Morten Wang FagerlandOslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital, Postboks 4950 Nydalen, 0424 Oslo, Norway.
Ida Unhammer NjerveCenter for Clinical Heart Research, Department of Cardiology, Oslo University Hospital, Ullevål, Postboks 4956 Nydalen, 0424 Oslo, Norway ; Faculty of Medicine, University of Oslo, Postboks 1078 Blindern, 0316 Oslo, Norway ; Center for Heart Failure Research, Institute for Experimental Medical Research, Oslo University Hospital, Ullevål, Kirkeveien 166, 0407 Oslo, Norway.
Harald ArnesenCenter for Clinical Heart Research, Department of Cardiology, Oslo University Hospital, Ullevål, Postboks 4956 Nydalen, 0424 Oslo, Norway ; Faculty of Medicine, University of Oslo, Postboks 1078 Blindern, 0316 Oslo, Norway ; Center for Heart Failure Research, Institute for Experimental Medical Research, Oslo University Hospital, Ullevål, Kirkeveien 166, 0407 Oslo, Norway.
Svein SolheimCenter for Clinical Heart Research, Department of Cardiology, Oslo University Hospital, Ullevål, Postboks 4956 Nydalen, 0424 Oslo, Norway ; Center for Heart Failure Research, Institute for Experimental Medical Research, Oslo University Hospital, Ullevål, Kirkeveien 166, 0407 Oslo, Norway.
Oslo University Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction. Fractalkine is a chemokine associated with atherosclerosis. Increased serum levels have been reported in unstable coronary artery disease (CAD) and to predict mortality in heart failure. Mediterranean-like diet and omega-3 fatty acids (n3-PUFA) have documented cardioprotective and anti-inflammatory effects. We have investigated the effect of Mediterranean-like dietary counseling and n-3 PUFA on serum fractalkine in an elderly population and its ability to predict cardiovascular disease (CVD). Materials and Methods. 563 men (age 64-75 yrs) at high risk of CAD were randomized into a 2 × 2 factorial designed trial for 3-year dietary counseling and/or n-3 PUFA supplementation (2.4 g/d). Circulating levels of fractalkine were measured at baseline and at end of study. Clinical events were recorded after 3 years. Results. Fractalkine levels were significantly reduced in all groups from baseline to 3 years (P < 0.001, all), but without between-group differences in changes. Fractalkine levels at baseline were not predictive for CVD events (n = 68) or total mortality. Lower fractalkine levels were observed in smokers (P = 0.019). Conclusions. Reduced levels of fractalkine from baseline to 3 years were observed, however, without any influence of Mediterranean-like diet or n-3 PUFA supplementation. Fractalkine levels at baseline were not predictive for later CVD events.

Indexed as

AgedCardiovascular DiseasesChemokine CX3CL1Dietary SupplementsFatty Acids, Omega-3HumansMaleMiddle AgedChemokine CX3CL1Fatty Acids, Omega-3

Identifiers

PMID25733777
PMCPMC4334932
OpenAlexW1994661889

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.